XERIS BIOPHARMA HOLDINGS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $339.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $176.00K, a 37.50% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $163.00K, a 38.14% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $151.00K, a 38.53% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $140.00K, a 32.08% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $537.00K, a 3.24% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $555.00K, a 33.13% decline from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $830.00K, a 94.84% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $426.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $339.00K 10-Q · filed 2026-08-06 | $490.00K derived: sum of 3 quarters · filed 2026-08-06 | $630.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $163.00K 10-Q · filed 2026-05-07 | $314.00K derived: sum of 2 quarters · filed 2026-05-07 | $454.00K derived: sum of 3 quarters · filed 2026-05-07 | $582.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $151.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $291.00K derived: sum of 2 quarters · filed 2026-03-02 | $419.00K derived: sum of 3 quarters · filed 2026-08-06 | $537.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $268.00K derived: sum of 2 quarters · filed 2026-08-06 | $386.00K 10-Q · filed 2025-11-06 | $495.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $128.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $246.00K 10-Q · filed 2026-08-06 | $355.00K derived: sum of 3 quarters · filed 2026-08-06 | $461.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $118.00K 10-Q · filed 2026-05-07 | $227.00K derived: sum of 2 quarters · filed 2026-05-07 | $333.00K derived: sum of 3 quarters · filed 2026-05-07 | $496.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $215.00K derived: sum of 2 quarters · filed 2026-03-02 | $378.00K derived: sum of 3 quarters · filed 2026-03-02 | $555.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $269.00K derived: sum of 2 quarters · filed 2025-11-06 | $446.00K 10-Q · filed 2025-11-06 | $648.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $163.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $340.00K 10-Q · filed 2025-08-07 | $542.00K derived: sum of 3 quarters · filed 2026-03-02 | $797.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $177.00K 10-Q · filed 2025-05-08 | $379.00K derived: sum of 2 quarters · filed 2026-03-02 | $634.00K derived: sum of 3 quarters · filed 2026-03-02 | $901.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $457.00K derived: sum of 2 quarters · filed 2026-03-02 | $724.00K derived: sum of 3 quarters · filed 2026-03-02 | $830.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $255.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $522.00K derived: sum of 2 quarters · filed 2024-11-08 | $628.00K 10-Q · filed 2024-11-08 | $1.05M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $267.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $373.00K 10-Q · filed 2024-08-08 | $799.00K derived: sum of 3 quarters · filed 2025-03-06 | $799.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $106.00K 10-Q · filed 2024-05-09 | $532.00K derived: sum of 2 quarters · filed 2025-03-06 | $532.00K derived: sum of 3 quarters · filed 2025-03-06 | $532.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $426.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $426.00K derived: sum of 2 quarters · filed 2025-03-06 | $426.00K derived: sum of 3 quarters · filed 2025-03-06 | $426.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |